Drugs / PDC-1421
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01774045 | Nov 2012 → Jul 2013 | major depressive disorder | BioLite, Inc. | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03833206 | Jan 2027 → Feb 2028 expected | major depressive disorder | BioLite, Inc. | Not yet recruiting | No outcome recorded |
| Phase 23 trials · 1 missed | ||||||
| Phase 2 | NCT05202327 | Apr 2022 → Dec 2023 | attention deficit-hyperactivity disorder | BioLite, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02699086 | Dec 2019 → Jul 2020 | attention deficit-hyperactivity disorder | BioLite, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT02395978 | Apr 2015 → Mar 2019 | major depressive disorder | BioLite, Inc. | Completed | Missed primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PDC-1421 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03833206 ↗ |
| Known as | PDC-1421 Capsule | “PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.” NCT02699086 ↗1“PDC-1421 Capsule is a botanical investigational new drug containing the extract of Radix Polygalae (Polygala tenuifolia Willd.) as active ingredient.” NCT03833206 ↗ |
| Route | Oral | “Frequency: once daily, p.o., after meal.” NCT01774045 ↗ |